MBX Biosciences, Inc. Increase (Decrease) in Other Operating Assets
MBX Biosciences, Inc. (MBX) reported Increase (Decrease) in Other Operating Assets of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-06
- MBX Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was -$43.00K, a 107.60% decline year-over-year.
- MBX Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $43.00K.
- MBX Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2025-06-30 was $566.00K.
- MBX Biosciences, Inc. increase (decrease) in other operating assets for the quarter ending 2025-03-31 was $0.00.
- MBX Biosciences, Inc. increase (decrease) in other operating assets for fiscal 2025 was -$8.00K.
- MBX Biosciences, Inc. increase (decrease) in other operating assets for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- MBX Biosciences, Inc. increase (decrease) in other operating assets for fiscal 2023 was $8.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|
| 2026-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $43.00K 10-Q · filed 2026-05-07 | ||
| 2025-12-31 | -$8.00K 10-K · filed 2026-03-12 | ||
| 2025-06-30 | $566.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $566.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 | ||
| 2023-12-31 | $8.00K 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |